HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Oncolytics Biotech (NASDAQ:ONCY) and maintained a price target of $5.
August 21, 2024 | 11:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Oncolytics Biotech and maintained a price target of $5, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $5 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Oncolytics Biotech's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100